CareDx, Inc. CDNA

CareDx (CDNA) is up about 14% today after BTIG raised its price target from $60 to $74 and maintained its Buy rating. That’s a big move for a target bump – and there may be even more upside to be had… The detailsBTIG hosted CareDx’s CEO, CFO, and head of investor relations for investor meetings in Boston earlier this week, and came away more bullish: Target raised 23%, from $60 to $74Management sounded confident after the positive resolution of the transplant local coverage determination (this i

Here is how CareDx (CDNA) and Concentra Group (CON) have performed compared to their sector so far this year.

CareDx (CDNA) stock has recently drawn attention after a sharp move in its share price. With returns over the past month and past 3 months well into double digits, investors are reassessing expectations. See our latest analysis for CareDx. Looking beyond the past month, CareDx has shown building momentum, with a 30.9% 1 month share price return, a 124.7% 3 month share price return and a 1 year total shareholder return of about 3.8x. The current share price of US$48.61 reflects a market that...

CareDx stock has delivered very strong gains over the past few years, yet the latest valuation checks and current market multiples point to a share price that leans expensive rather than clearly cheap. For investors, that raises the question of how much of the recent share price strength already reflects expectations that are built into the current valuation. CareDx has returned around 4.6x over the past 3 years, which makes any new entry point far more sensitive to how much is already...